PAS free stock reports
Posted in News
In the October 2017 newsletter we highlighted new reports that could be used to check if Trusts had obtained free stock where a Patient Access Scheme included an element of free stock according to preset criteria for each drug.
We have reviewed the applicability of the golimumab reports, as free stock had historically been associated with the use of higher doses of golimumab for patients weighting more than 100kg, but has been replaced in practice by the provision of the higher dose at the same price as the lower dose.
The PAS reports and the associated Flags for golimumab formulations have been removed.